To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The primary objective of this study is to assess and compare the pharmacokinetics (PK) of Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day), SPIRIVA�, HandiHaler�, (18 mcg/day) and Respimat� Soft Mist� Inhaler (SMI) (5.0 mcg/day) following repeat dosing for 7 days in subjects with COPD.